Candesartan cilexetil loaded nanodelivery systems for improved oral bioavailability

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Andrew JH, William N. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv. Drug Deliv. Rev. 25, 103–128 (1997). • A comprehensive review describing the selection of different lipid-based delivery approaches for improvement of oral bioavailability of Biopharmaceutics Classification System class II and IV drugs.
  Google Scholar
• 2 Zhang L, Wang S, Zhang M, Sun J. Nanocarriers for oral drug delivery. J. Drug Target. 21, 515–527 (2013).
  Medline CASGoogle Scholar
• 3 Christoph HG, Klaus EM. Clinical pharmacokinetics of candesartan. Clin. Pharmacokin. 41, 7–17 (2002). • Describes the pharmacokinetics and dose-related effects of candesartan.
  Google Scholar
• 4 Prisant LM, Elliott WJ. Drug delivery systems for treatment of systemic hypertension. Clin. Pharmacokin. 42, 931–940 (2003).
  Medline CASGoogle Scholar
• 5 Jain N, Jain R, Thakur N. Nanotechnology: a safe and effective drug delivery system. Asian. J. Pharm. Clin. Res. 3, 159–165 (2010).
  CASGoogle Scholar
• 6 Sharma M, Sharma R, Jain DK. Nanotechnology based approaches for enhancing oral bioavailability of poorly water soluble antihypertensive drugs. Scientifica (Cairo) doi:30;2016:8525679, 1–11 (2016).
  Google Scholar
• 7 Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp. Mol. Path. 86, 215–223 (2009).
  Medline CASGoogle Scholar
• 8 Shaji J, Bhatia V. Novel lipid carriers for oral delivery of lipophilic drugs. Int. J. Pharm. Sci. Rev. Res. 15, 47–53 (2012).
  CASGoogle Scholar
• 9 Mohanraj VJ, Chen Y. Nanoparticles-a review. Tro. J. Pharma. Res. 5, 561–573 (2006).
  Google Scholar
• 10 Mudshinge SR, Deore AB, Patil S, Bhalgat CM. Nanoparticles: emerging carriers for drug delivery. Saudi Pharma. J. 19, 129–141 (2011).
  Medline CASGoogle Scholar
• 11 Bamrungsap S, Zhao Z, Chen T et al. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomed. 7, 1253–1271 (2012).
  Medline CASGoogle Scholar
• 12 Gautama SP, Verma A. PAMAM dendrimers: novel polymeric nanoarchitectures for solubility enhancement of candesartan cilexetil. Pharma. Sci. 1, 1–4 (2012).
  Google Scholar
• 13 Vijaykumar N, Raviraj P, Venkateshwarlu V, Harisudhan T. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles. Pharm. Dev. Tech. 14, 290–298 (2009). •• Emphasizes the role of nanosuspension for enhancement of oral bioavailability and also industrial scale up of formulation.
  MedlineGoogle Scholar
• 14 Satturwar P, Eddine MN, Ravenelle F, Leroux JC. pH-responsive polymeric micelles of poly(ethylene glycol)- b-poly(alkyl(meth)acrylate-co-methacrylic acid): influence of the copolymer composition on self-assembling properties and release of candesartan cilexetil. Eur. J. Pharma. Biopharm. 65, 379–387 (2007).
  Medline CASGoogle Scholar
• 15 Aylin G, Nuray Y, Ayla Ç, Belma T. Trimethyl chitosan nanoparticles enhances dissolution of the poorly water soluble drug candesartan-cilexetil. Macromol. Res. 18, 986–991 (2010).
  Google Scholar
• 16 Müller RH, Jacobs C, Kayser O. Nanosuspension as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3–19 (2001).
  Medline CASGoogle Scholar
• 17 Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmcol. 56, 827–840 (2004).
  Medline CASGoogle Scholar
• 18 Chetan D, Sandip CS. Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study. Sci. Pharm. 79, 635–651 (2011).
  MedlineGoogle Scholar
• 19 Mahesh RD, Umang KG, Daval DM, Kalpesh AP, Rai M, Sheth NR. Formulation, optimization and characterization of candesartan cilexetil nanosuspension for in vitro dissolution enhancement. Afr. J. Pharm. Pharmcol. 9, 102–113 (2015). •• Describes the dose-related effect of drug in the form of nanosuspension for enhancement of oral bioavailability.
  Google Scholar
• 20 Mühlen AZ, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 45, 149–155 (1998). • An excellent review providing information on the drug-release mechanisms from solid lipid nanoparticles (SLNs).
  MedlineGoogle Scholar
• 21 Mehnert W, Mäder K. Solid lipid nanoparticles production, characterization and applications. Adv. Drug Deliv. Rev. 47, 165–196 (2001).
  Medline CASGoogle Scholar
• 22 Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int. J. Nanomed. 2, 289–300 (2007).
  MedlineGoogle Scholar
• 23 Arik D, Amnon H. Rationalizing the selection of oral lipid based drug-delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J. Control. Rel. 129, 1–10 (2008). • An excellent review providing information on the mechanisms for enhancement of absorption from the SLNs in biological systems.
  MedlineGoogle Scholar
• 24 Narendar D, Kishan V. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv. 23, 395–404 (2016). •• Describes the role of SLN delivery in prolonging the candesartan cilexetil drug effect, improved pharmacodynamic effect. It is of clinical importance for doctors and patients.
  MedlineGoogle Scholar
• 25 Narendar D. Preparation characterization and in-vivo evaluation of solid lipid nanoparticles of some anti-hypertensive and other drugs. PhD thesis submitted to Kakatiya University (2015).
  Google Scholar
• 26 Zhang Z, Gao F, Bu H, Xiao J, Li Y. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Nanomed. 8, 740–747 (2012).
  Medline CASGoogle Scholar
• 27 Beloqui A, Solinís MÁ, Delgado A, Evora C, Isla A, Rodríguez-Gascón A. Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution. J. Microencapsul. 31, 1–8 (2014).
  Medline CASGoogle Scholar
• 28 Hetal TP, Jagruti DL, Mayur PP. Application of Box-Behnken design for optimization of formulation parameters for nanostructured lipid carriers of candesartan cilexetil. Asian. J. Pharm. 8, 81–9 (2014).
  Google Scholar
• 29 Kim CK, Cho YJ, Gao ZG. Preparation and evaluation of biphenyl dimethyl dicarboxylate microemulsions for oral delivery. J. Control. Rel. 70, 149–155 (2001).
  Medline CASGoogle Scholar
• 30 Manjit J, Rupesh D, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. Biotech. 5, 123–127 (2015).
  Google Scholar
• 31 Gao F, Zhang Z, Bu H et al. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism. J. Control. Rel. 149, 168–74 (2011).
  Medline CASGoogle Scholar
• 32 Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. Self emulsifying drug-delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int. J. Pharm. 106, 15–23 (1994).
  CASGoogle Scholar
• 33 Vijaykumar N, Pradeep K, Raghavendra P, Raviraj P. Solid self-microemulsifying formulation for candesartan cilexetil. AAPS Pharm. Sci. Tech. 11, 9–17 (2010).
  MedlineGoogle Scholar
• 34 Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of niosomes-non ionic surfactant vesicles. J. Pharm. Pharmacol. 37, 863–868 (1985).
  Medline CASGoogle Scholar
• 35 Zerrin SB, Mustafa NA, Nilufer Y. Development and characterization of mixed niosomes for oral delivery using candesartan cilexetil as a model poorly water-soluble drug. AAPS PharmSciTech. 16, 108–117 (2015).
  MedlineGoogle Scholar